Nasoryl M (Xylometazoline Hydrochloride, Ipratropium Bromide)

Nasoryl M combines a decongestant and an anticholinergic to address conditions within the rhinitis spectrum.

• Nasal congestion: reduces swelling of nasal mucosa to improve airflow.
• Allergic rhinitis: limits reflex nasal secretions and eases blockage caused by allergens.
• Non‑allergic rhinitis: diminishes mucosal edema and excessive discharge, supporting clearer breathing.

• Xylometazoline Hydrochloride acts as an alpha‑adrenergic agonist, causing vasoconstriction of the nasal submucosal vessels and thereby decreasing mucosal edema. Ipratropium Bromide blocks muscarinic receptors on nasal glands, inhibiting acetylcholine‑mediated secretions and reducing rhinorrhoea. The combined actions provide rapid decongestion and secretory control within the nasal passages.

Nasoryl M may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nasal irritation or burning sensation.
• Dryness of the nasal mucosa.
• Sneezing or mild epistaxis.
• Bitter taste after administration.
• Headache.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis) with swelling, rash, or difficulty breathing.
• Persistent hypertension or tachycardia.
• Nasal ulceration or perforation with prolonged use.
• Acute angle‑closure glaucoma exacerbation.
• Cardiac arrhythmias in susceptible individuals.

Before using Nasoryl M, consider the following safety measures.

• Pregnancy: consult a healthcare professional before use.
• Breastfeeding: discuss potential risks with a physician.
• Duration of use: limit to 3–5 days to avoid rebound congestion.
• Pre‑existing conditions: avoid in patients with narrow‑angle glaucoma or severe hypertension.
• Concomitant nasal surgery: postpone use until healing is complete.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nasoryl M can interact with other medications that affect vascular tone or cholinergic pathways.

Major Interactions (Avoid)

• Systemic alpha‑adrenergic agonists: additive vasoconstrictive effects may raise blood pressure.
• Other intranasal decongestants: risk of excessive vasoconstriction and rebound congestion.
• Strong anticholinergic drugs: may increase anticholinergic burden leading to dry mouth or blurred vision.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may blunt systemic cardiovascular responses.

• Antihypertensive agents: monitor blood pressure for potential elevation.
• Monoamine oxidase inhibitors (MAOIs): observe for hypertensive episodes.